EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The propositive study: Immunogenicity and safety of a four‐component recombinant protein‐based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living with HIV

Catherine Isitt, Angela Bartolf, Nick Andrews, Shehnaz Athaide, Richard Pryce-Williams, Kelly Townsend-Payne, Ray Borrow, Shamez Ladhani, Paul T Heath, Catherine A Cosgrove

HIV Medicine · 2023

DOI: 10.1111/hiv.13495 ↗

Kurz gefasst

Fachartikel in der Zeitschrift HIV Medicine, 2023. Verfasst von Catherine Isitt und 9 weiteren Autor:innen. Beteiligte Einrichtung: Vaccine Institute, St. George's University of London & St George's University Hospital NHS Trust, London, UK. Hauptthemen laut MEDLINE: Meningococcal Vaccines, Meningococcal Infections, HIV Infections. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: GlaxoSmithKline.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

People living with HIV have been shown to have an increased risk of invasive meningococcal disease. In some countries, meningococcal vaccines are now routinely recommended to all people living with HIV, but no study has yet assessed the immunogenicity and safety of a meningococcal serogroup B vaccine or the co‐administration of a MenB and MenACWY vaccine in people living with HIV.

Methods

This phase IV open‐label clinical trial investigated the immunogenicity and safety of two doses of a four‐component recombinant protein‐based MenB vaccine (4CMenB) and a quadrivalent conjugate polysaccharide MenACWY vaccine (MenACWY‐CRM197) given 1 month apart in a population of people living with HIV. Immunogenicity analysis was performed before vaccination and 1 month after the second doses of 4CMenB and MenACWY. Primary outcome measures were serum bactericidal assay geometric mean titres against three MenB reference strains at baseline and 1 month post vaccination, the proportion of participants achieving a putative protective titre of ≥4, and the proportion of participants with a ≥4‐fold rise in titre from baseline. Secondary outcome measures were serum bactericidal assay geometric mean titres against MenA, C, W, and Y reference strains at baseline and 1 month post vaccination, the proportion achieving a putative protective titre of ≥8, and the proportion with a ≥4‐fold rise in titre from baseline. Safety outcomes were solicited and unsolicited adverse events in the 7 days following vaccination. The trial was registered with clinicaltrials.gov (NCT03682939).

Findings

In total, 55 participants aged 20–45 years were enrolled. All participants (100%; 95% confidence interval [CI] 93–100) achieved putative protective titres for two of the three MenB strains and for MenA, W, and Y. A total of 98% (95% CI 89–100) achieved a protective titre for the third MenB strain and 94% (95% CI 83–99) for MenC. No serious adverse events were reported.

Interpretation

4CMenB and MenACWY were immunogenic and well‐tolerated in a population of people living with HIV 1 month after two doses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Meningococcal VaccinesMeningococcal InfectionsHIV InfectionsHumansVaccines, CombinedRecombinant ProteinsVaccines, Conjugate

Stichwörter der Autor:innen

HIVmeningococcal diseasevaccines

Substanzen

Meningococcal VaccinesVaccines, CombinedRecombinant ProteinsMenACWYVaccines, Conjugate

Autor:innen und Institutionen

  • Vaccine Institute, St. George's University of London & St George's University Hospital NHS Trust, London, UK.
  • United Kingdom Health Security Agency, Colindale, UK.
  • United Kingdom Health Security Agency, Vaccine Evaluation Unit, Manchester, UK.
  • Centre for Neonatal and Paediatric Infection, St. George's University of London, London, UK.

Förderung

  • GlaxoSmithKline

Zitieren

APA

Isitt, C., Bartolf, A., Andrews, N., Athaide, S., Pryce-Williams, R., Townsend-Payne, K., Borrow, R., Ladhani, S., Heath, P. T., & Cosgrove, C. A. (2023). The propositive study: Immunogenicity and safety of a four‐component recombinant protein‐based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living with HIV. HIV Medicine. https://doi.org/10.1111/hiv.13495

Vancouver

Isitt C, Bartolf A, Andrews N, Athaide S, Pryce-Williams R, Townsend-Payne K, et al. The propositive study: Immunogenicity and safety of a four‐component recombinant protein‐based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living with HIV. HIV Medicine. 2023. doi:10.1111/hiv.13495

BibTeX
@article{Isitt2023,
  author = {Isitt, Catherine and Bartolf, Angela and Andrews, Nick and Athaide, Shehnaz and Pryce-Williams, Richard and Townsend-Payne, Kelly and Borrow, Ray and Ladhani, Shamez and Heath, Paul T and Cosgrove, Catherine A},
  title = {The propositive study: Immunogenicity and safety of a four‐component recombinant protein‐based vaccine against MenB and a quadrivalent conjugate MenACWY vaccine in people living with HIV},
  journal = {HIV Medicine},
  year = {2023},
  doi = {10.1111/hiv.13495}
}
Kostenlos starten →